SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-21-024773
Filing Date
2021-05-06
Accepted
2021-05-06 07:14:00
Documents
59
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0321_protara.htm 10-Q 657069
2 RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY f10q0321ex10-1_protara.htm EX-10.1 11471
3 EXECUTIVE EMPLOYMENT AGREEMENT, EFFECTIVE AS OF APRIL 19, 2021 BY AND BETWEEN TH f10q0321ex10-2_protara.htm EX-10.2 61132
4 CERTIFICATION f10q0321ex31-1_protara.htm EX-31.1 14811
5 CERTIFICATION f10q0321ex31-2_protara.htm EX-31.2 16120
6 CERTIFICATION f10q0321ex32-1_protara.htm EX-32.1 6709
  Complete submission text file 0001213900-21-024773.txt   3126327

Data Files

Seq Description Document Type Size
7 XBRL INSTANCE FILE tara-20210331.xml EX-101.INS 330483
8 XBRL SCHEMA FILE tara-20210331.xsd EX-101.SCH 46928
9 XBRL CALCULATION FILE tara-20210331_cal.xml EX-101.CAL 30045
10 XBRL DEFINITION FILE tara-20210331_def.xml EX-101.DEF 202623
11 XBRL LABEL FILE tara-20210331_lab.xml EX-101.LAB 370003
12 XBRL PRESENTATION FILE tara-20210331_pre.xml EX-101.PRE 212837
Mailing Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010 646-844-0337
Protara Therapeutics, Inc. (Filer) CIK: 0001359931 (see all company filings)

IRS No.: 204580525 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36694 | Film No.: 21895760
SIC: 2836 Biological Products, (No Diagnostic Substances)